USA – Interline Therapeutics, a San Francisco, CA-based drug discovery company, raised $92M in funding.
The round was led by Foresite Capital and ARCH Venture Partners.The company intends to use the funds to expand the research platform and advance six preclinical therapeutic programs.Co-founded by CEO Zachary Sweeney, Interline Therapeutics is a Foresite Labs incubated company that focuses on systematically elucidating protein communities to define molecular mechanisms of disease. The company uses genomics, proteomics, structural biology and computational chemistry to systematically map and modulate protein communities. Interline Therapeutics is leveraging recent advancements in these technologies, as well as collaborations with academic groups, to develop a precision medicine platform focused on three essential areas:The discovery platform will allow the company to identify new medicines targeting genetically validated signaling pathways and ensure that drug candidates comprehensively correct dysfunctional disease networks.The team includes Nick Galli, Chief Operating Officer, Don Kirkpatrick, Chief Technology Officer, Mario Cardozo, Vice President Computational Chemistry and Cheminformatics, Anj Saha, Vice President Discovery Pharmacology and David Tully, Vice President Medicinal Chemistry.The company will continue to collaborate with Foresite Labs in the fields of data science and genomics. Interline also launches with foundational collaborations with University of California San Francisco and Memorial Sloan Kettering Cancer Center, as well as an internationally recognized team of founding scientific advisors, including:13/05/2021
